KING CHULALONGKORN MEMORIAL HOSPITAL

The VANCE trial, the largest T cell therapy clinical trial for solid tumors, demonstrates Singapore's capability in large-scale global cell therapy. Published in 'Annals on Oncology' (2024), it shows no overall survival improvement but highlights potential for subgroup refinement and biomarker identification.

Largest T cell therapy trial for solid tumours, led by Singapore, showed no overall survival benefit but better outcomes in US, Singapore, and Taiwan sites. Identifying biomarkers could enhance therapy success.

The VANCE trial, a multinational phase III study led by Singapore, concludes that T cell therapy for solid tumours is safe but requires refinement to improve outcomes. The trial, published in Annals on Oncology, involved 330 patients across 23 sites, showing no overall survival benefit but potential in specific subgroups. Future efforts aim to identify biomarkers for personalized T cell therapy.

The Undiagnosed Hackathon was conceptualized and designed by H.C., M. Cederroth, A.N., and A.M.D.V. Biological samples and phenotype data were collected by various authors, processed and analyzed under the coordination of A.M.D.V. et al. All authors participated in data analysis and interpretation, with A.M.D.V. et al. drafting the manuscript. A.N., H.C., and M. Cederroth secured funding.

Taiwan's DCB and BPIPO, led by President Shiing-Jer Twu and Director Michael Huang, participated in Bio Asia Pacific 2024 in Bangkok, promoting biotech collaboration. The Taiwan-Thailand Biotechnology Industry Technical Engagement Forum highlighted innovations in precision medicine, genetic testing, and personalized healthcare. Networking events and facility visits reinforced Taiwan's commitment to strengthening ties with Thailand in biotechnology and pharmaceutical sectors.

Thailand showcased biotech advancements in precision medicine, CAR-T therapy, and wellness at Bio Asia Pacific, highlighting APAC leadership. Key developments include CAR-T cell research, genomic services, and eco-friendly medical supplies. Strategic meetings discussed biopharmaceutical production and precision medicine collaborations between Taiwan and Thailand. MP Group expanded from diagnostics to wellness, while King Chulalongkorn Memorial Hospital focused on CAR-T cell therapy. N-Health, Thailand’s largest private healthcare operator, offers comprehensive genomic services. TCELS drives life sciences innovation, and Thailand aims for globalization and health equity in 2024.